Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health director Steve E. Krognes reported equity compensation activity. On June 17, 2026, 4,203 Restricted Stock Units fully vested in connection with the company’s 2026 Annual Meeting of Stockholders and were converted into an equal number of shares of common stock.
Following this derivative exercise, Krognes held 14,425 shares of Guardant Health common stock directly. On the same date, he also received a new grant of 2,711 Restricted Stock Units, each representing a right to receive one share of common stock that will vest in full on the earlier of June 17, 2027 or the company’s next annual stockholder meeting.
Guardant Health, Inc. director Meghan V. Joyce reported the vesting and settlement of a restricted stock unit award into common stock. On June 17, 2026, coinciding with the company’s 2026 Annual Meeting of Stockholders, 4,203 restricted stock units converted into 4,203 shares of common stock at no exercise price. Following this compensation-related transaction, Joyce directly holds 15,386 shares of Guardant Health common stock, and no open-market purchases or sales were reported in this filing.
Guardant Health director Manuel Hidalgo Medina reported compensation-related equity activity on June 17, 2026. He exercised vested restricted stock units to acquire 4,435 shares of Common Stock at a conversion price of $0.00 per share and received a new grant of 2,711 restricted stock units. Following these transactions, one reported line shows direct ownership of 5,074 Common Stock shares and 2,711 restricted stock units, reflecting routine vesting and grants rather than open-market trading.
Guardant Health, Inc. director Vijaya Gadde reported routine equity compensation activity. On June 17, 2026, Gadde exercised restricted stock units covering 4,203 shares of Common Stock, increasing direct holdings to 28,517 shares. On the same date, Gadde also received a new award of 2,711 restricted stock units that will vest in full on the earlier of the one-year anniversary of the June 17, 2026 grant date or the company’s next annual meeting of stockholders.
Guardant Health director Ian T. Clark reported equity compensation activity tied to the 2026 Annual Meeting of Stockholders. A previously granted restricted stock unit (RSU) award vested in full on June 17, 2026 and was exercised into 5,092 shares of common stock, bringing indirect holdings in a family trust to 8,067 shares.
Clark also received a new grant of 2,711 RSUs on June 17, 2026. These RSUs convert into the same number of common shares and are scheduled to vest in full on the one-year anniversary of the grant date or on the date of Guardant Health’s next annual stockholder meeting, whichever occurs earlier. All reported transactions are acquisitions related to awards rather than open-market buying or selling.
Azar Alex M II reported acquisition or exercise transactions in this Form 4 filing.
Guardant Health director Azar Alex M II received a grant of 2,711 Restricted Stock Units (RSUs) tied to the company’s common stock. Each RSU represents the right to receive one share of common stock for no cash payment. The award vests in full on June 17, 2026, the one-year anniversary of the grant date, or on the date of Guardant Health’s next annual meeting of stockholders, whichever occurs earlier. Following this Form 4 transaction, Azar holds 2,711 RSUs directly.
Guardant Health filed a Form 144 disclosing restricted stock lapses and related sales by an individual. The filing lists three reported transactions by Musa Tariq on 04/16/2026 (9,840.00), 05/18/2026 (11,131.00), and 06/16/2026 (15,102.00) tied to equity compensation and a restricted stock lapse dated 06/18/2026.
Guardant Health, Inc. notice of proposed sales under Form 144 by an affiliate. The filing lists an employee stock option exercise of 2,000 shares settled via a broker payment for a cashless exercise on 06/22/2026, a restricted stock lapse of 4,203 shares on 06/17/2026, and a reported sale of 10,000 shares on 06/03/2026 for $1,269,809.00.
Guardant Health, Inc. reported results of its June 17, 2026 annual stockholder meeting. Stockholders elected all director nominees, including Ian Clark with 70,526,891 votes for and Manuel Hidalgo Medina with 81,925,123 votes for, with broker non-votes recorded on each.
Stockholders approved the ratification of Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, with 115,899,030 votes for. An advisory vote to approve compensation of named executive officers was not approved, receiving 98,236,639 votes for and 9,905,190 votes against. In an advisory vote on the frequency of future say-on-pay votes, most votes were cast for one year, with 107,997,996 votes for that option.